Neuronal basis of neuroleptic-induced extrapyramidal side effects

Polish Journal of Pharmacology

Volumn 54, Issue 4, 2002, Pages 299-312

  Ossowska, Krystyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Basal ganglia; D1 receptor; D2 receptor; Genetic predisposition; Lesion; Neuroleptic; Parkinsonism; Supersensitivity to dopamine; Tardive dyskinesia

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; BENPERIDOL; CHLORPROMAZINE; CLOZAPINE; CYPROHEPTADINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; KETANSERIN; MESULERGINE; METHYSERGIDE; MIANSERIN; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; RITANSERIN; SERTINDOLE; SPIPERONE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE; DOPAMINE RECEPTOR BLOCKING AGENT;

AGED; ANIMAL TISSUE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EXPERIMENTAL ANIMAL; EXTRAPYRAMIDAL SYMPTOM; GENETIC PREDISPOSITION; HUMAN; MOUSE; NERVE CELL LESION; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; REVIEW; SUPERSENSITIVITY; TARDIVE DYSKINESIA; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DYSKINESIA; EXTRAPYRAMIDAL SYSTEM; GENETICS; METABOLISM; SENSORY NERVE;

AFFERENT PATHWAYS; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; EXTRAPYRAMIDAL TRACTS; HUMANS; PARKINSONIAN DISORDERS;

EID: 0036382278     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Andreassen O.A., Finsen B., Østergaard K., West M.J., Jørgensen H.A.: Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long-term haloperidol administration. Neurosci. Lett., 2000, 279, 21-24.
2. 2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem., 1992, 58, 1104-1109.
3. Angulo J.A., Cadet J.L., Wooley C.S., Suber F., McEwen B.S.: Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat. J. Neurochem., 1990, 54, 1889-1894.
4. Auchus A.P., Pickel V.M.: Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp. Neurol., 1992, 117, 17-27.
5. Baldessarini R.J.: Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics. Eds. Gilman A.G., Goodman L.S., Rall T.W., Murad F., Macmillan Publ. Comp., New York, 1985, 387-445.
6. Balijepalli S., Boyd M.R., Ravindranath V: Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology, 1999, 38, 567-577.
7. Balk J.-H., Picetti R., Salardi A., Thirlet G., Dierich A., Depaulis A., Le Meur M., Borelli E.: Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature, 1995, 377, 424-428.
8. Balsara J.J., Jadhav J.H., Chandorkar A.G.: Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology, 1979, 62, 67-69.
9. Barrientos A., Marín C., Miró Ò., Casademont J., Gómez M., Nunes V., Tolosa E., Urbano-Marquez A., Cardellach F.: Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats. J. Neurosci. Res., 1998, 53, 475-481.
10. Basile V.S., Masellis M., Badri F., Paterson A.D., Meltzer H.Y., Lieberman J.A., Potkin S.G., Macciardi F., Kennedy J.L.: Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology, 1999, 21, 17-27.
11. Basile V.S., Ozdemir V., Masellis M., Walker M.L., Meltzer H.Y., Lieberman J.A., Potkin S.G., Alva G., Kalow W., Macciardi F.M., Kennedy J.L.: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiat., 2000, 5, 410-417.
12. Basura G.J., Walker P.D.: Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion. Mol. Brain Res., 2001, 92, 66-77.
13. Bauer R., Mayr A., Lederer W., Needham P., Kilpatrick I.G., Fleischhacker W.W., Marksteiner J.: Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antypsychotic drugs. Neuropharmacology, 2000, 23, 46-55.
14. Burkhardt C., Kelly J.P., Lim Y.-H., Filley C.M., Parker W.D. Jr.: Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol., 1993, 33, 512-517.
15. Casey D.E.: Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in non-human primates. Psychopharmacology, 1993, 112, S55-S59.
16. Cenci M.A., Lee C.S., Björklund A.: L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 1999, 10, 2694-2706.
17. Egan M.F., Hurd Y., Fergusson J., Bacus S.E., Hamid E.H., Hyde T.M.: Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology, 1996, 127, 337-345.
18. Egan M.F., Hurd Y., Hyde T.M., Weinberger D.R., Wyatt R.J., Kleinman J.E.: Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse, 1994, 18, 178-189.
19. Ehringer H., Hornykiewicz O.: Verleitung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr., 1960, 38, 1236-1239.
20. Ellison G., Johansson P., Levin E., See R., Gunne L.: Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats. Psychopharmacology, 1988, 96, 253-257.
21. Engber T.M., Susel Z., Kuo S., Gerfen C.R., Chase T.N.: Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res., 1991, 552, 113-118.
22. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiat., 1992, 49, 538-544.
23. Gerfen C.R.: The neostriatal mosaic levels of compartmental organization. Trends Neurosci., 1992, 15, 33-139.
24. Grimm J.W., Chapman M.A., Zahm D.S., See R.E.: Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following haloperidol in rats. Synapse, 2001, 39, 51-57.
25. Gunne L.M., Andrën P.E.: An animal model for co-existing tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin. Neuropharmacol., 1993, 16, 90-95.
26. Gunne L.M., Häggström J.E., Sjöquist B.: Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature, 1984, 309, 347-349.
27. Hicks P.B.: The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci., 1990, 47, 1609-1615.
28. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., Nakamura J.: Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology, 2000, 23, 170-177.
29. Janssen P.A.J., Niemegeers C.J.E., Schellenkens K.H.L.: Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Arzneim.-Forsch.-Drug Res., 1965, 15, 104-117.
30. Jeste D.V., Lohr J.B., Manley M.: Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology, 1992, 106, 154-160.
31. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Amer. J. Psychiat. 1999, 156, 286-293.
32. 123I-IBZM SPECT study. Psychopharmacology, 1998, 136, 367-373.
33. Korsgaard S., Gerlach J., Christensson E.: Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur. J. Pharmacol., 1985, 118, 245-252.
34. Kostowski W., Gumulka W., Członkowski A.: Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res., 1972, 48, 443-446.
35. Küfferle B., Tauscher J., Asenbaum S., Vesely C., Podreka I., Brücke T., Kasper S.: IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology, 1997, 133, 323-328.
36. 2 receptor occupancy and extrapyramidal side effects. Eur. Neuropsychopharmacol., 1997, 7, S128-S129.
37. Liao D.L., Yeh Y.C., Chen H.M., Chen H., Hong C.J., Tsai S.J.: Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 2001, 44, 95-98.
38. Liste I., Muńoz A., Guerra M.J., Labandeira-Garcia J.: Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems. Synapse, 2000, 35, 182-191.
39. Mahadik S.P., Laev H., Korenovsky A., Karpiak S.E.: Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analysis. Biol. Psychiat., 1988, 24, 199-217.
40. Marcus M.M., Nomikos G.G., Malmerfelt A., Zachrisson O., Lindefors N., Svensson T.H.: Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate-putamen of the rat. Brain Res., 1997, 45, 275-282.
41. Maurer I., Moller H.J.: Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem., 1997, 174, 255-259.
42. 2 receptor occupancy under recommended and high doses of olanzapine; an iodine - 123-iodobenzamide SPECT study. J. Psychopharmacol., 2000, 14, 364-370.
43. Mercugliano M., Chesselet M.F.: Clozapine decreases enkephalin mRNA in rat striatum. Neurosci. Lett., 1992, 136, 10-14.
44. Mijnster M.J., Raimundo A.G., Koskuba K., Klop H., Docter G.J., Groenewegen H.J., Voorn P.: Regional and cellular distribution of serotonin 5-hydroxytryptamine 2A receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat. J. Comp. Neurol., 1997, 389, 1-11.
45. Mijnster M., J., Schotte A., Doctor G.J., Voorn P.: Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate-putamen and nucleus accumbens of the rat. Synapse, 1998, 28, 302-312.
46. Mitchell I.J., Cooper A.C., Griffiths M.R., Cooper A.J.: Acute administration of haloperidol induces apoptosis of neurons in the striatum and substantia nigra in the rat. Neuroscience, 2002, 109, 89-99.
47. Mizuno Y.: Mitochondrial energy crisis as a mechanism for nigral cell death. In: Parkinson's Disease. From Clinical Aspects to Molecular Basis. Eds. Nagatsu T., Narabayashi H., Yoshida M., Springer Verlag, Wien, New York, 1991, 61-72.
48. 2 receptor deficient mice. Neuroscience, 2000, 99, 643-650.
49. Nielsen E.B., Lyon M.: Evidence for cell loss in copus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology, 1978, 59, 85-89.
50. 2 receptor occupancy. Studies and clinical response. Brit. J. Psychiat., 1996, 168, Suppl. 29, 40-44.
51. Ossowska K.: Disturbances in neurotransmission processes in aging and age-related diseases. Pol. J. Pharmacol., 1993, 45, 109-131.
52. Pakkenberg H., Fog R., Nilakantan B.: The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations. Psychopharmacology, 1973, 29, 329-336.
53. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X., el Mestikawy S., Hamon M., Descarries L: Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol., 2000, 417, 181-194.
54. Robertson G.S., Fibiger H.C.: Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience, 1992, 46, 315-328.
55. Robertson G.S., Matsumura H., Fibiger H.C.: Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther., 1994, 271, 1058-1066.
56. Rosengarten H., Schweitzer J.W., Friedhoff A.J.: Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci., 1983, 33, 2479-2482.
57. Rosengarten H., Schweitzer J.W., Friedhoff A.J.: The effect of novel antipsychotics in rat oral dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiat., 1999, 23, 1389-1404.
58. Sakai K., Gao X.-M., Hashimoto T., Tamminga C.A.: Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia - thalamocortical neural pathways. Synapse, 2001, 39, 152-160.
59. Schmidt C.J., Sorensen S.M., Kehne J.H., Carr A.A., Palfreyman M.G.: The role of 5-HT2A receptors in antipsychotic activity. Life Sci., 1995, 56, 2209-2222.
60. See R.E.: The role of neurotransmitter receptors in the adverse effects of antipsychotic drugs. In: Neurotransmitter Receptors in Actions of Antipsychotic Medications. Pharmacology and Toxicology: Basic and Clinical Aspects. Ed. Lidow M.S. CRC Press, Boca Raton, London, New York, Washington, DC, 2000, 221-242.
61. A and dopamine D2, but not dopamine D1 receptors. Life Sci., 1989, 44, 229-236.
62. See R.E., Toga A.W., Ellison G.: Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. Neural Transm.-Gen. Sect., 1990, 82, 93-109.
63. Seeman P.: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987, 1, 133-152.
64. Seeman P: Antipsychotic drugs, dopamine D2 receptor, and schizophrenia. In: Neurotransmitter Receptors in Actions of Antipsychotic Medications. Pharmacology and Toxicology: Basic and Clinical Aspects. Ed. Lidow M.S. CRC Press, Boca Raton, London, New York, Washington, DC, 2000, 43-63.
65. Seeman P., Niznik H.B.: Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J., 1990, 4, 2737-2744.
66. Segman R.H., Heresco-Levy U., Finkel B., Goltser T., Shalem R., Schlafman M., Dorevitch A., Yakir A., Greenberg D., Lerner A., Lerer B.: Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiat., 2001, 6, 225-229.
67. Segman R.H., Heresco-Levy U., Finkel B., Inbar R., Neeman T., Schlafman M., Dorevitch A., Yakir A., Lerner A., Goltser T., Shelovoy A., Lerer B.: Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2C and DRD3gly alleles to susceptibility. Psychopharmacology, 2000, 152, 408-413.
68. Silvestri S., Seeman M.V., Negrete J.-C., Houle S., Shammi C.M., Remington G.J., Kapur S., Zipursky R.B., Wilson A.A., Christensen B.K., Seeman P.: Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET studies. Psychopharmacology, 2000, 152, 174-180.
69. Smith A.D., Bolam J.P.: The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci., 1990, 13, 259-265.
70. Stoessl A.J., Dourish C.T., Iversen S.D.: Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. Psychopharmacology, 1989, 98, 372-379.
71. Subramanyan B., Rollema H., Woolf T., Castagnoli N. Jr.: Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun., 1990, 166, 238-244.
72. Tan E.-C., Chong S.-A., Mahendran R., Dong F., Tan C.-H.: Susceptibility to neuroleptic tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol. Psychiat., 2001, 50, 144-147.
73. Tarazi F.I., Zhang K., Baldessarini R.J.: Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther., 2001, 297, 711-717.
74. 2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. Brit. J. Psychiat., 1997, 171, 290-291.
75. Van Kampen J.M., Stoessl A.J.: Dopamine D1A receptor function in a rodent model of tardive dyskinesia. Neuroscience, 2000, 101, 3, 629-635.
76. Walker P.D., Capodilupo J.G., Wolf W.A., Carlock L.R.: Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Res., 1996, 732, 25-35.
77. Ward R.P., Dorsa D.M.: Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol., 1996, 370, 405-414.
78. Wolfarth S., Ossowska K.: Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuro-Psych. Biol. Psych., 1989, 13, 799-840.
79. Wolfarth S., Ossowska K.: Tardive dyskinesia: theory of supersensitivity to dopamine and newer hypotheses. In: Schizophrenic psychoses and antipsychotic drugs. VII Winter School. Eds. Przegalińiski E., Wójcik E., Institute of Pharmacology, Polish Academy of Sciences, Mogilany, 1990, 167-187.
80. Zeng B.-Y., Jolkkonen J., Jenner P., Marsden C.D.: Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin, and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience, 1995, 66, 19-28.